Does the media prefer PGNY or HIMS?

In the previous week, Progyny had 1 more articles in the media than Hims & Hers Health. MarketBeat recorded 11 mentions for Progyny and 10 mentions for Hims & Hers Health. Progyny's average media sentiment score of 0.88 beat Hims & Hers Health's score of 0.83 indicating that Progyny is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Progyny 3 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hims & Hers Health 6 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, PGNY or PACS?

PACS Group has higher revenue and earnings than Progyny. PACS Group is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Progyny $1.29B 1.86 $58.52M $0.77 39.81 PACS Group $5.29B 1.29 $191.54M $1.56 27.72

Is PGNY or PACS more profitable?

Progyny has a net margin of 5.23% compared to PACS Group's net margin of 4.49%. PACS Group's return on equity of 26.47% beat Progyny's return on equity. Company Net Margins Return on Equity Return on Assets Progyny 5.23% 13.34% 9.03% PACS Group 4.49% 26.47% 4.36%

Does the media prefer PGNY or PACS?

In the previous week, PACS Group had 12 more articles in the media than Progyny. MarketBeat recorded 23 mentions for PACS Group and 11 mentions for Progyny. Progyny's average media sentiment score of 0.88 beat PACS Group's score of 0.01 indicating that Progyny is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Progyny 3 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PACS Group 7 Very Positive mention(s) 5 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, PGNY or BLLN?

Progyny has higher revenue and earnings than Billiontoone. Progyny is trading at a lower price-to-earnings ratio than Billiontoone, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Progyny $1.29B 1.86 $58.52M $0.77 39.81 Billiontoone $305.11M 19.11 $7.45M $0.55 230.49

Does the media refer more to PGNY or BLLN?

In the previous week, Progyny had 4 more articles in the media than Billiontoone. MarketBeat recorded 11 mentions for Progyny and 7 mentions for Billiontoone. Progyny's average media sentiment score of 0.88 beat Billiontoone's score of -0.05 indicating that Progyny is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Progyny 3 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Billiontoone 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, RDNT or PGNY?

Progyny has lower revenue, but higher earnings than RadNet. RadNet is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio RadNet $2.04B 2.53 -$18.65M -$0.18 N/A Progyny $1.29B 1.86 $58.52M $0.77 39.81

Is RDNT or PGNY more profitable?

Progyny has a net margin of 5.23% compared to RadNet's net margin of -0.66%. Progyny's return on equity of 13.34% beat RadNet's return on equity. Company Net Margins Return on Equity Return on Assets RadNet -0.66% 2.77% 0.97% Progyny 5.23% 13.34% 9.03%

Does the media refer more to RDNT or PGNY?

In the previous week, Progyny had 9 more articles in the media than RadNet. MarketBeat recorded 11 mentions for Progyny and 2 mentions for RadNet. RadNet's average media sentiment score of 1.38 beat Progyny's score of 0.88 indicating that RadNet is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RadNet 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Progyny 3 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, CELC or PGNY?

Progyny has higher revenue and earnings than Celcuity. Celcuity is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Celcuity N/A N/A -$177.04M -$3.90 N/A Progyny $1.29B 1.86 $58.52M $0.77 39.81

Is CELC or PGNY more profitable?

Progyny has a net margin of 5.23% compared to Celcuity's net margin of 0.00%. Progyny's return on equity of 13.34% beat Celcuity's return on equity. Company Net Margins Return on Equity Return on Assets Celcuity N/A -244.61% -50.22% Progyny 5.23% 13.34% 9.03%

Does the media favor CELC or PGNY?

In the previous week, Progyny had 9 more articles in the media than Celcuity. MarketBeat recorded 11 mentions for Progyny and 2 mentions for Celcuity. Celcuity's average media sentiment score of 1.88 beat Progyny's score of 0.88 indicating that Celcuity is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celcuity 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Progyny 3 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Progyny (PGNY) Competitors

$30.65 -0.42 (-1.35%)

Closing price 07/10/2026 04:00 PM Eastern

Extended Trading

$30.98 +0.33 (+1.06%)

As of 07/10/2026 07:17 PM Eastern

Compare

PGNY vs. HIMS, PACS, BLLN, RDNT, and CELC

Should you buy Progyny stock or one of its competitors? MarketBeat compares Progyny with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Progyny include Hims & Hers Health (HIMS), PACS Group (PACS), Billiontoone (BLLN), RadNet (RDNT), and Celcuity (CELC). These companies are all part of the "healthcare" industry.

How does Progyny compare to Hims & Hers Health?

Progyny (NASDAQ:PGNY) and Hims & Hers Health (NYSE:HIMS) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, media sentiment, profitability and earnings.

In the previous week, Progyny had 1 more articles in the media than Hims & Hers Health. MarketBeat recorded 11 mentions for Progyny and 10 mentions for Hims & Hers Health. Progyny's average media sentiment score of 0.88 beat Hims & Hers Health's score of 0.83 indicating that Progyny is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Progyny	3 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hims & Hers Health	6 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Progyny has a net margin of 5.23% compared to Hims & Hers Health's net margin of -0.56%. Progyny's return on equity of 13.34% beat Hims & Hers Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Progyny	5.23%	13.34%	9.03%
Hims & Hers Health	-0.56%	6.10%	1.52%

Progyny presently has a consensus target price of $30.09, indicating a potential downside of 1.82%. Hims & Hers Health has a consensus target price of $30.70, indicating a potential downside of 10.88%. Given Progyny's stronger consensus rating and higher probable upside, research analysts clearly believe Progyny is more favorable than Hims & Hers Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Progyny	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92
Hims & Hers Health	2 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.13

Progyny has a beta of 1.01, indicating that its share price is 1% more volatile than the broader market. Comparatively, Hims & Hers Health has a beta of 2.35, indicating that its share price is 135% more volatile than the broader market.

94.9% of Progyny shares are held by institutional investors. Comparatively, 63.5% of Hims & Hers Health shares are held by institutional investors. 9.9% of Progyny shares are held by company insiders. Comparatively, 11.8% of Hims & Hers Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Hims & Hers Health has higher revenue and earnings than Progyny. Hims & Hers Health is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Progyny	$1.29B	1.86	$58.52M	$0.77	39.81
Hims & Hers Health	$2.35B	3.40	$128.37M	-$0.09	N/A

Summary

Progyny beats Hims & Hers Health on 12 of the 17 factors compared between the two stocks.

How does Progyny compare to PACS Group?

Progyny (NASDAQ:PGNY) and PACS Group (NYSE:PACS) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment.

Progyny has a net margin of 5.23% compared to PACS Group's net margin of 4.49%. PACS Group's return on equity of 26.47% beat Progyny's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Progyny	5.23%	13.34%	9.03%
PACS Group	4.49%	26.47%	4.36%

Progyny has a beta of 1.01, meaning that its share price is 1% more volatile than the broader market. Comparatively, PACS Group has a beta of -0.08, meaning that its share price is 108% less volatile than the broader market.

Progyny presently has a consensus price target of $30.09, indicating a potential downside of 1.82%. PACS Group has a consensus price target of $50.60, indicating a potential upside of 17.02%. Given PACS Group's higher probable upside, analysts clearly believe PACS Group is more favorable than Progyny.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Progyny	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92
PACS Group	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71

PACS Group has higher revenue and earnings than Progyny. PACS Group is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Progyny	$1.29B	1.86	$58.52M	$0.77	39.81
PACS Group	$5.29B	1.29	$191.54M	$1.56	27.72

In the previous week, PACS Group had 12 more articles in the media than Progyny. MarketBeat recorded 23 mentions for PACS Group and 11 mentions for Progyny. Progyny's average media sentiment score of 0.88 beat PACS Group's score of 0.01 indicating that Progyny is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Progyny	3 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PACS Group	7 Very Positive mention(s)	5 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

94.9% of Progyny shares are held by institutional investors. 9.9% of Progyny shares are held by insiders. Comparatively, 70.1% of PACS Group shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Progyny beats PACS Group on 10 of the 17 factors compared between the two stocks.

How does Progyny compare to Billiontoone?

Progyny (NASDAQ:PGNY) and Billiontoone (NASDAQ:BLLN) are both mid-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, institutional ownership, risk and profitability.

Progyny has higher revenue and earnings than Billiontoone. Progyny is trading at a lower price-to-earnings ratio than Billiontoone, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Progyny	$1.29B	1.86	$58.52M	$0.77	39.81
Billiontoone	$305.11M	19.11	$7.45M	$0.55	230.49

Progyny has a net margin of 5.23% compared to Billiontoone's net margin of 0.00%. Progyny's return on equity of 13.34% beat Billiontoone's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Progyny	5.23%	13.34%	9.03%
Billiontoone	N/A	N/A	N/A

94.9% of Progyny shares are owned by institutional investors. 9.9% of Progyny shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Progyny currently has a consensus target price of $30.09, indicating a potential downside of 1.82%. Billiontoone has a consensus target price of $126.00, indicating a potential downside of 0.61%. Given Billiontoone's higher possible upside, analysts plainly believe Billiontoone is more favorable than Progyny.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Progyny	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92
Billiontoone	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Progyny had 4 more articles in the media than Billiontoone. MarketBeat recorded 11 mentions for Progyny and 7 mentions for Billiontoone. Progyny's average media sentiment score of 0.88 beat Billiontoone's score of -0.05 indicating that Progyny is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Progyny	3 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Billiontoone	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Progyny beats Billiontoone on 13 of the 16 factors compared between the two stocks.

How does Progyny compare to RadNet?

RadNet (NASDAQ:RDNT) and Progyny (NASDAQ:PGNY) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, risk, valuation, profitability and analyst recommendations.

Progyny has lower revenue, but higher earnings than RadNet. RadNet is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RadNet	$2.04B	2.53	-$18.65M	-$0.18	N/A
Progyny	$1.29B	1.86	$58.52M	$0.77	39.81

Progyny has a net margin of 5.23% compared to RadNet's net margin of -0.66%. Progyny's return on equity of 13.34% beat RadNet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RadNet	-0.66%	2.77%	0.97%
Progyny	5.23%	13.34%	9.03%

RadNet has a beta of 1.37, suggesting that its share price is 37% more volatile than the broader market. Comparatively, Progyny has a beta of 1.01, suggesting that its share price is 1% more volatile than the broader market.

77.9% of RadNet shares are owned by institutional investors. Comparatively, 94.9% of Progyny shares are owned by institutional investors. 5.6% of RadNet shares are owned by company insiders. Comparatively, 9.9% of Progyny shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

RadNet currently has a consensus target price of $87.43, indicating a potential upside of 33.28%. Progyny has a consensus target price of $30.09, indicating a potential downside of 1.82%. Given RadNet's higher probable upside, equities analysts clearly believe RadNet is more favorable than Progyny.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RadNet	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90
Progyny	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92

In the previous week, Progyny had 9 more articles in the media than RadNet. MarketBeat recorded 11 mentions for Progyny and 2 mentions for RadNet. RadNet's average media sentiment score of 1.38 beat Progyny's score of 0.88 indicating that RadNet is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RadNet	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Progyny	3 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Progyny beats RadNet on 11 of the 17 factors compared between the two stocks.

How does Progyny compare to Celcuity?

Celcuity (NASDAQ:CELC) and Progyny (NASDAQ:PGNY) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk, dividends and media sentiment.

Progyny has a net margin of 5.23% compared to Celcuity's net margin of 0.00%. Progyny's return on equity of 13.34% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celcuity	N/A	-244.61%	-50.22%
Progyny	5.23%	13.34%	9.03%

Progyny has higher revenue and earnings than Celcuity. Celcuity is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celcuity	N/A	N/A	-$177.04M	-$3.90	N/A
Progyny	$1.29B	1.86	$58.52M	$0.77	39.81

Celcuity has a beta of 0.16, meaning that its stock price is 84% less volatile than the broader market. Comparatively, Progyny has a beta of 1.01, meaning that its stock price is 1% more volatile than the broader market.

In the previous week, Progyny had 9 more articles in the media than Celcuity. MarketBeat recorded 11 mentions for Progyny and 2 mentions for Celcuity. Celcuity's average media sentiment score of 1.88 beat Progyny's score of 0.88 indicating that Celcuity is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celcuity	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Progyny	3 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

63.3% of Celcuity shares are held by institutional investors. Comparatively, 94.9% of Progyny shares are held by institutional investors. 13.3% of Celcuity shares are held by insiders. Comparatively, 9.9% of Progyny shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Celcuity currently has a consensus target price of $152.09, indicating a potential upside of 41.37%. Progyny has a consensus target price of $30.09, indicating a potential downside of 1.82%. Given Celcuity's higher probable upside, equities analysts plainly believe Celcuity is more favorable than Progyny.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celcuity	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.83
Progyny	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92

Summary

Progyny beats Celcuity on 12 of the 16 factors compared between the two stocks.

Get Progyny News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PGNY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PGNY vs. The Competition

Export

Metric	Progyny	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.43B	$9.59B	$7.14B	$12.64B
Dividend Yield	N/A	1.63%	2.68%	7.83%
P/E Ratio	39.81	26.41	27.42	24.58
Price / Sales	1.86	18.14	593.42	121.62
Price / Cash	42.20	114.05	49.34	60.04
Price / Book	5.12	6.05	10.88	6.38
Net Income	$58.52M	$179.69M	$3.59B	$331.87M
7 Day Performance	1.42%	-1.68%	-0.26%	0.37%
1 Month Performance	19.49%	6.63%	4.52%	0.53%
1 Year Performance	32.06%	11.95%	29.17%	21.96%

Progyny Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PGNY Progyny	3.6992 of 5 stars	$30.65 -1.4%	$30.09 -1.8%	+29.8%	$2.43B	$1.29B	39.81	310	News Coverage Analyst Upgrade
HIMS Hims & Hers Health	2.7693 of 5 stars	$38.34 +4.2%	$30.63 -20.1%	-31.4%	$8.52B	$2.35B	N/A	2,442	Analyst Forecast Insider Trade
PACS PACS Group	3.2973 of 5 stars	$44.68 +0.5%	$48.00 +7.4%	+238.1%	$7.04B	$5.29B	28.51	47,455	Analyst Forecast Insider Trade
BLLN Billiontoone	1.7386 of 5 stars	$123.40 +2.5%	$126.00 +2.1%	N/A	$5.54B	$305.11M	N/A	620	Insider Trade
RDNT RadNet	3.7058 of 5 stars	$68.92 +0.2%	$87.43 +26.9%	+14.1%	$5.41B	$2.04B	N/A	11,264

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PGNY) was last updated on 7/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Progyny (PGNY) Competitors

PGNY vs. HIMS, PACS, BLLN, RDNT, and CELC

How does Progyny compare to Hims & Hers Health?

Summary

How does Progyny compare to PACS Group?

Summary

How does Progyny compare to Billiontoone?

Summary

How does Progyny compare to RadNet?

Summary

How does Progyny compare to Celcuity?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PGNY vs. The Competition

Progyny Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Progyny (PGNY) Competitors

PGNY vs. HIMS, PACS, BLLN, RDNT, and CELC

How does Progyny compare to Hims & Hers Health?

Does the media prefer PGNY or HIMS?

Is PGNY or HIMS more profitable?

Do analysts prefer PGNY or HIMS?

Which has more volatility and risk, PGNY or HIMS?

Do insiders & institutionals believe in PGNY or HIMS?

Which has better earnings & valuation, PGNY or HIMS?

Summary

How does Progyny compare to PACS Group?

Is PGNY or PACS more profitable?

Which has more volatility & risk, PGNY or PACS?

Do analysts recommend PGNY or PACS?

Which has preferable valuation & earnings, PGNY or PACS?

Does the media prefer PGNY or PACS?

Do institutionals and insiders believe in PGNY or PACS?

Summary

How does Progyny compare to Billiontoone?

Which has stronger earnings and valuation, PGNY or BLLN?

Is PGNY or BLLN more profitable?

Do institutionals and insiders believe in PGNY or BLLN?

Do analysts recommend PGNY or BLLN?

Does the media refer more to PGNY or BLLN?

Summary

How does Progyny compare to RadNet?

Which has better earnings & valuation, RDNT or PGNY?

Is RDNT or PGNY more profitable?

Which has more risk & volatility, RDNT or PGNY?

Do institutionals & insiders have more ownership in RDNT or PGNY?

Do analysts rate RDNT or PGNY?

Does the media refer more to RDNT or PGNY?

Summary

How does Progyny compare to Celcuity?

Is CELC or PGNY more profitable?

Which has higher earnings & valuation, CELC or PGNY?

Which has more volatility & risk, CELC or PGNY?

Does the media favor CELC or PGNY?

Do institutionals & insiders believe in CELC or PGNY?

Do analysts prefer CELC or PGNY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PGNY vs. The Competition

Progyny Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools